Table 1 Cohort characteristics.
Total cohort (N = 99) | Intensively treated (N = 87) | Non-intensively treated (N = 12) | |
|---|---|---|---|
Age, y | |||
Median | 53.0 | 51.0 | 75.5 |
IQR | 40.0–67.0 | 37.0–64.0 | 60.0–78.5 |
Range | 19–80 | 19–79 | 43–80 |
Sex, n (%) | |||
Male | 61 (61.6%) | 54 (62.8%) | 6 (50%) |
Female | 38 (38.4%) | 32 (37.2%) | 6 (50%) |
WHO Performance Score, n (%) | |||
0-1 | 92 (93.8%) | 84 (96.7%) | 8 (66.7%) |
2-4 | 6 (6.1%) | 2 (2.0%) | 4 (33.3%) |
nd | 1 (1%) | 1 (1.0%) | 0 (0%) |
Prior cytotoxic treatment, n (%) | |||
Yes | 11 (11.1%) | 9 (10.3%) | 2 (16.7%) |
No | 88 (88.9%) | 78 (89.7%) | 10 (83.3%) |
Extramedullary disease, n (%) | |||
Yes | 3 (3.0%) | 3 (3.4%) | 0 (0%) |
No | 96 (97.0%) | 84 (96.6%) | 12 (100%) |
Hemoglobin, mmol/L | |||
Mean | 5.5 | 5.5 | 6.0 |
IQR | 4.9–6.5 | 4.8–6.3 | 4.9–7.5 |
Platelets, 109/L | |||
Median | 33.0 | 32.0 | 35.5 |
IQR | 17.5–69.0 | 17.5–59.5 | 14.0–96.5 |
Leukocytes, 109/L | |||
Median | 9.1 | 9.9 | 3.5 |
IQR | 3.7–18.8 | 4.4–19.7 | 1.9–15.2 |
LDH at diagnosis, U/I | |||
Median | 501 | 539 | 408 |
IQR | 314 – 998 | 330–1028 | 213–871 |
Peripheral blood blasts, % | |||
Mean | 36.3 | 38.3 | 23.9 |
IQR | 11.5 – 56.0 | 18.5–56.5 | 4.8–34.5 |
Bone marrow blasts, % | |||
Mean | 50.0 | 49.5 | 53.3 |
IQR | 32.0 – 69.0 | 35.0–67.0 | 30.0–77.0 |
Allogeneic stem cell transplantation, n (%) | |||
Yes | 11 (11.2%) | 11 (12.8%) | 0 (0%) |
CR1 | 2 (18.2%) | 2 (18.2%) | 0 (0%) |
CR2 | 9 (81.8%) | 9 (81.8%) | 0 (0%) |
No | 87 (88.8%) | 75 (87.2%) | 12 (100%) |
